New Antibiotics Recognized as a 'Major Shift' in Addressing Drug-Resistant Gonorrhoea
The first new treatments for gonorrhoea in a generation are being hailed as a "huge turning point" in the fight against superbug strains of the pathogen, according to researchers.
An International Health Concern
Gonorrhoea infections are increasing globally, with figures suggesting in excess of 82 million instances each year. Especially elevated rates are seen in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were three times higher compared to figures for 2014.
“The clearance of novel therapies for gonorrhoea is an important and timely advancement in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options currently available.”
Health officials are increasingly worried about the rise in treatment-resistant strains. The World Health Organization has classified it as a "critical concern". A tracking program found that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.
Two New Therapies Gain Clearance
One new antibiotic, alternatively called a brand name, was cleared by the US Food and Drug Administration in December for use against gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers anticipate that specific application of this new drug will help delay the spread of drug resistance.
Another new antibiotic, developed by the drugmaker GlaxoSmithKline, gained clearance in the same week. This drug, which is employed against urinary tract infections, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.
A Novel Approach to Creation
Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP partnered with the drug firm Innoviva to develop it.
“This authorization signifies a major breakthrough in the management of superbug gonorrhoea, which up to this point has been outpacing medical innovation.”
Research Study Data and Worldwide Availability
Based on results detailed in a prominent scientific publication, zoliflodacin cured over nine in ten of cases of the STI. This puts it on an comparable level with the existing first-line therapy, which involves an injection and a pill. The study involved nearly 1,000 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.
Through the arrangement of its unique model, GARDP has the rights to license and sell the drug in a wide range of low-income and middle-income countries.
Medical professionals on the front lines have shared positive views. Having a one-pill regimen like this is described as a "critical tool" for public health efforts. This is deemed vital to alleviate the strain of the disease for people and to halt the transmission of extremely resistant gonorrhoea around the world.